Author

N. B. Erdmann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1

Frequent Co-Authors

C. Ye· 3 shared J. J. Kobie· 3 shared L. Martinez-Sobrido· 3 shared M. Basu· 3 shared M. R. Walter· 3 shared M. S. Piepenbrink· 3 shared P. A. Goepfert· 3 shared S. Sarkar· 3 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

C. Ye

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Potent neutralization by a receptor binding domain monoclonal antibody with broad specificity for SARS-CoV-2 JN.1 and other variants

M. S. Piepenbrink, A. M. Khalil, A. Chang, A. Mostafa, M. Basu, S. Sarkar, S. Panjwani, Y. H. Ha, Y. Ma, C. Ye, Q. Wang, T. J. Green, J. L. Kizziah, N. B. Erdmann, P. A. Goepfert, , J. J. Kobie

This study develops a monoclonal antibody that broadly neutralizes multiple SARS-CoV-2 variants, including JN.1, and shows its protective efficacy in mice.

bioRxiv · Apr 27, 2024 · PreprintImmunology

Potent universal-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody

M. S. Piepenbrink, J.-G. Park, A. Deshpande, A. Loos, C. Ye, M. Basu, S. Sarkar, D. Chauvin, J. Woo, P. Lovalenti, N. B. Erdmann, P. A. Goepfert, V. L. Truong, R. A. Bowen, M. R. Walter, , J. J. Kobie

This study identifies a potent universal coronavirus neutralizing monoclonal antibody, 1249A8, effective against multiple variants and demonstrating therapeutic activity through intranasal administration.

bioRxiv · Mar 5, 2022 · PreprintImmunology

Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters

M. S. Piepenbrink, J.-G. Park, F. Oladunni, A. Deshpande, M. Basu, S. Sarkar, A. Loos, J. Woo, P. Lovalenti, D. Sloan, C. Ye, K. Chiem, N. B. Erdmann, P. A. Goepfert, V. L. Truong, , J. J. Kobie

This study evaluates an inhaled monoclonal antibody against SARS-CoV-2 in hamsters, showing reduced viral burden and lung pathology with low-dose inhalation.

bioRxiv · Oct 14, 2020Immunology